Law.com Subscribers SAVE 30%

Call 855-808-4530 or email [email protected] to receive your discount on a new subscription.

The Intellectual Property StrategistKickerFeaturesTopicsCommercial LawTechnology Media and TelecomSectionsNewsLJN Newsletters

Medimmune: New Rules for Patent Licenses?

By John Cone
February 28, 2007

The Supreme Court's Medimmune decision relates directly to the federal courts' jurisdictional requirement of case or controversy, but by overruling the Federal Circuit's Gen-Probe decision it may also have changed the balance of power between patentees and licensees.

Medimmune's Synagis' drug accounted for 80% of its sales revenue. Genentech claimed that a patent license to Medimmune under Genentech's Cabilly II patent entitled it to royalties on those sales. Medimmune considered the patent invalid, but did not want to repudiate the license and risk an injunction, treble damages, and attorneys' fees and so paid royalties on sales of the SYNAGIS drug 'under protest.' Was there an 'actual controversy' between Medimmune and Genen- tech to provide jurisdictional basis for a declaratory judgment action or the issues of patent infringement and validity? 'No,' held the Federal Circuit, on the basis of
its earlier Gen-Probe decision, because the license protected Medimmune from the reasonable apprehension of a lawsuit. Medimmune, Inc. v. Genentech, Inc., 427 F.3d 958, 964, 965 (Fed. Cir. 2005). The Supreme Court, however, reversed, holding that Medimmune did not have to 'bet the farm' by repudiating the license in order to provide the jurisdictional basis for a federal declaratory judgment action. Medimmune, Inc. v. Genentech, Inc., 127 S. Ct. 764 (2007).

This premium content is locked for Entertainment Law & Finance subscribers only

  • Stay current on the latest information, rulings, regulations, and trends
  • Includes practical, must-have information on copyrights, royalties, AI, and more
  • Tap into expert guidance from top entertainment lawyers and experts

For enterprise-wide or corporate acess, please contact Customer Service at [email protected] or 877-256-2473

Read These Next
Why So Many Great Lawyers Stink at Business Development and What Law Firms Are Doing About It Image

Why is it that those who are best skilled at advocating for others are ill-equipped at advocating for their own skills and what to do about it?

Bankruptcy Sales: Finding a Diamond In the Rough Image

There is no efficient market for the sale of bankruptcy assets. Inefficient markets yield a transactional drag, potentially dampening the ability of debtors and trustees to maximize value for creditors. This article identifies ways in which investors may more easily discover bankruptcy asset sales.

The DOJ's Corporate Enforcement Policy: One Year Later Image

The DOJ's Criminal Division issued three declinations since the issuance of the revised CEP a year ago. Review of these cases gives insight into DOJ's implementation of the new policy in practice.

A Lawyer's System for Active Reading Image

Active reading comprises many daily tasks lawyers engage in, including highlighting, annotating, note taking, comparing and searching texts. It demands more than flipping or turning pages.

Blockchain Domains: New Developments for Brand Owners Image

Blockchain domain names offer decentralized alternatives to traditional DNS-based domain names, promising enhanced security, privacy and censorship resistance. However, these benefits come with significant challenges, particularly for brand owners seeking to protect their trademarks in these new digital spaces.